Entering text into the input field will update the search result below

Sage Therapeutics, Biogen report positive zuranolone data in late-stage depression study

Dec. 01, 2021 6:56 AM ETBiogen Inc. (BIIB), SAGEBy: SA News Team

Book with title Major depressive disorder.

designer491/iStock via Getty Images

  • Sage Therapeutics (NASDAQ:SAGE) and Biogen (NASDAQ:BIIB) announce 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their initial dose in Phase 3 SHORELINE Study in major depressive

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.